Adele Collin

Adele Collin studied engineering and biomedical science in France before gaining experience in academia and biotech companies. Her notable experiences include PBPK modeling of monoclonal antibody treatments at NovaDiscovery and developing machine learning models to predict the likelihood of alcoholic patients dropping out of rehabilitation centers at MEDAL. She is committed to making protocol and drug development more efficient in order to make personalized treatment options available to all. 

Her research interests include computational methods for drug discovery and artificial intelligence for biomedical research. 

Previous Education: